{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:31:12Z","timestamp":1770816672270,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.joms.2011.02.104","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T09:05:12Z","timestamp":1311930312000},"page":"632-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Osteonecrosis After Administration of Intravitreous Bevacizumab"],"prefix":"10.1016","volume":"70","author":[{"given":"Renato Nicol\u00e1s","family":"Hopp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Roger","family":"Santos-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacks","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2011.02.104_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.joms.2011.02.104_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajo.2006.03.036","article-title":"Intravitreal Avastin: The low cost alternative to Lucentis?","volume":"142","author":"Rosenfeld","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.joms.2011.02.104_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1590\/S1516-31802009000200006","article-title":"Bevacizumab for ocular neovascular diseases: A systematic review","volume":"127","author":"Andriolo","year":"2009","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.joms.2011.02.104_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1188\/09.CJON.564-572","article-title":"Oncology nursing in a new era: Optimizing treatment with bevacizumab","volume":"13","author":"Marrs","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.joms.2011.02.104_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.joms.2011.02.104_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463200902200429","article-title":"Bevacizumab-related osteonecrosis of the jaw","volume":"22","author":"Serra","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.joms.2011.02.104_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.joms.2011.02.104_bib8","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"20","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2011.02.104_bib9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2011.02.104_bib10","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.004","article-title":"Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: A matched study","volume":"122","author":"Hou","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.joms.2011.02.104_bib11","article-title":"Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study","author":"Lim","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.joms.2011.02.104_bib12","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International intravitreal bevacizumab Safety Survey: Using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.joms.2011.02.104_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","article-title":"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration","volume":"27","author":"Mordenti","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.joms.2011.02.104_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.joms.2011.02.104_bib15","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Penetration of bevacizumab through the retina after intravitreal injection in the monkey","volume":"48","author":"Heiduschka","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.joms.2011.02.104_bib16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.joms.2011.02.104_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.joms.2011.02.104_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.joms.2011.02.104_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00002512-200926040-00002","article-title":"Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence?","volume":"26","author":"Ziemssen","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.joms.2011.02.104_bib20","first-page":"200","article-title":"Updates on osteonecrosis of the jaw","volume":"4","author":"Yamashita","year":"2010","journal-title":"J Palliat Care"},{"key":"10.1016\/j.joms.2011.02.104_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/02770909909065152","article-title":"The pathogenesis of osteonecrosis and the relationships to corticosteroids","volume":"36","author":"Mirzai","year":"1999","journal-title":"J Asthma"},{"key":"10.1016\/j.joms.2011.02.104_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.joms.2011.02.104_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.joms.2010.03.011","article-title":"How new knowledge sounds: Developing a contemporary understanding of osteonecrosis","volume":"68","author":"Assael","year":"2010","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239111003326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239111003326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:38:11Z","timestamp":1759509491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239111003326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0278239111003326"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2011.02.104","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis After Administration of Intravitreous Bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2011.02.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}